Disease · MONDO_0001531

blood coagulation disease

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. blood coagulation disease. Diseases, record MONDO_0001531. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001531

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: blood coagulation disease; Open Targets
Open Targets ID: MONDO_0001531; Open Targets
Other names: blood coagulation disorder, clotting disorder, coagulation defect, coagulation disorder, coagulation disorder, blood, coagulation disorders, blood, coagulopathy, disorder, blood coagulation, disorders, blood coagulation, excessive bleeding, postpartum coagulation defect, postpartum coagulation defect with delivery; Open Targets
Disease Ontology: DOID:1247; Disease Ontology
MeSH: D001778; MeSH
NCI Thesaurus: C2902; NCI Thesaurus
Highest stage of its drugs: Approval, for 12 of its 38 drugs, from FDA and TTD; Open Targets

Drugs38

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
TRANEXAMIC ACID	CHEMBL877	Small molecule	Approval	TTD	4	3	3	Drugs and targets
HEPARIN	CHEMBL4650299	Oligosaccharide	Approval	TTD	3	2	2	Drugs and targets
HEPARIN CALCIUM	CHEMBL1201513	Oligosaccharide	Approval	TTD	2	1	0	Drugs and targets
HEPARIN SODIUM	CHEMBL1201657	Oligosaccharide	Approval	TTD	2	1	0	Drugs and targets
NADROPARIN CALCIUM	CHEMBL2109204	Oligosaccharide	Approval	TTD	2	1	0	Drugs and targets
ANISINDIONE	CHEMBL712	Small molecule	Approval	TTD	1	0	0	Drugs and targets
ANTITHROMBIN III HUMAN	CHEMBL2108574		Approval	TTD	1	0	0	Drugs and targets
DESIRUDIN	CHEMBL1201662	Protein	Approval	TTD	1	0	0	Drugs and targets
MENADIOL SODIUM DIPHOSPHATE	CHEMBL3989728	Small molecule	Approval	TTD	1	0	0	Drugs and targets
PHENINDIONE	CHEMBL711	Small molecule	Approval	TTD	1	0	0	Drugs and targets

1 to 10 of 38

See all 38 drugs

Targets16

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SERPINC1	Antithrombin-III	7	Antithrombin-III activator	Approval	https://conductscience.org/library/genes/462	Drugs and targets
F10	Coagulation factor X	5	Coagulation factor X exogenous protein; Coagulation factor X inhibitor	Phase 3	https://conductscience.org/library/genes/2159	Drugs and targets
F2	Prothrombin	5	Thrombin exogenous protein; Thrombin inhibitor	Approval	https://conductscience.org/library/genes/2147	Drugs and targets
PLG	Plasminogen	2	Plasminogen inhibitor	Approval	https://conductscience.org/library/genes/5340	Drugs and targets
VKORC1	Vitamin K epoxide reductase complex subunit 1	2	Vitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor	Approval	https://conductscience.org/library/genes/79001	Drugs and targets
ELANE	Neutrophil elastase	1	Leukocyte elastase inhibitor	Phase 2	https://conductscience.org/library/genes/1991	Drugs and targets
F2R	Proteinase-activated receptor 1	1	Proteinase-activated receptor 1 antagonist	Phase 1/2	https://conductscience.org/library/genes/2149	Drugs and targets
F7	Coagulation factor VII	1	Coagulation factor VII exogenous protein	Phase 3	https://conductscience.org/library/genes/2155	Drugs and targets
F9	Coagulation factor IX	1	Coagulation factor IX exogenous protein	Phase 3	https://conductscience.org/library/genes/2158	Drugs and targets
FGA	Fibrinogen	1	Fibrinogen exogenous protein	Phase 3	https://conductscience.org/library/genes/2243	Drugs and targets

1 to 10 of 16

See all 16 targets

Trials18

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT04362085	Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care	Phase 3	465	2025-01-30	COVID-19	DALTEPARIN SODIUM, ENOXAPARIN, ENOXAPARIN SODIUM, HEPARIN, TINZAPARIN	Its record names the disease	ClinicalTrials.gov
NCT00708435	Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy	Phase 3	216	2013-08-13	Blood Coagulation Disorders, Acute Major Bleeding	PROTHROMBIN COMPLEX CONCENTRATE	Its record names the disease	ClinicalTrials.gov
NCT02394730	Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints	Phase 1/2	65	2019-02-28	HIV	VORAPAXAR	Its record names the disease	ClinicalTrials.gov
NCT03932240	In Vivo Effects of Fibrinogen Concentrate (FC) Versus Cryoprecipitate on the Neonatal Fibrin Network Structure After Cardiopulmonary Bypass (CPB)	Phase 3	36	2023-03-20	Hemostasis	FIBRINOGEN, HUMAN	Its record names the disease	ClinicalTrials.gov
NCT06235749	Administration Of Calcium Gluconate for The Reduction of Blood Loss During Elective Cesarean Delivery	Not applicable	1,180		Elective Cesarean Delivery	CALCIUM GLUCONATE	Its record names the disease	ClinicalTrials.gov
NCT00162435	Genetic Determinants of Warfarin Anticoagulation Effect	Not applicable	500		Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation	WARFARIN	Its record names the disease	ClinicalTrials.gov
NCT04444700	A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic	Phase 3	465		COVID, Coronavirus Infection, Severe Acute Respiratory Syndrome, Thromboembolism, Venous, Anticoagulants and Bleeding Disorders	DALTEPARIN SODIUM, ENOXAPARIN, HEPARIN, TINZAPARIN	Its record names the disease	ClinicalTrials.gov
NCT00396760	Comparison of Aprotinin and Tranexamic Acid in Routine Cardiac Surgery	Phase 3	220		Bleeding and Cardiac Surgery, Allogeneic Blood Transfusion, Aortic Valve Replacement, Coronary Artery Bypass Graft Surgery	APROTININ, TRANEXAMIC ACID	Its record names the disease	ClinicalTrials.gov
NCT04345848	Preventing COVID-19 Complications With Low- and High-dose Anticoagulation	Phase 3	160		COVID, Sars-CoV2	ENOXAPARIN	Its record names the disease	ClinicalTrials.gov
NCT04508439	Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection	Not applicable	130		Covid19, Pneumonia, Coagulation Disorder, Pulmonary Embolism	ENOXAPARIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 18

See all 18 trials

Comparisons in its trials25

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Therapeutic Anticoagulation vs Standard Care: All-cause Death	4 of 228	18 of 237	465	NCT04362085	Trial comparisons
Therapeutic Anticoagulation vs Standard Care: Composite Outcome of ICU Admission or All-cause Death	4 of 228	1 of 237	465	NCT04362085	Trial comparisons
Therapeutic Anticoagulation vs Standard Care: Composite Outcome of Mechanical Ventilation or All-cause Death	23 of 228	28 of 237	465	NCT04362085	Trial comparisons
Therapeutic Anticoagulation vs Standard Care: Major Bleeding	2 of 228	4 of 237	465	NCT04362085	Trial comparisons
Therapeutic Anticoagulation vs Standard Care: Arterial Thromboembolism	0 of 228	1 of 237	465	NCT04362085	Trial comparisons
Therapeutic Anticoagulation vs Standard Care: Heparin Induced Thrombocytopenia	0 of 228	0 of 237	465	NCT04362085	Trial comparisons
Therapeutic Anticoagulation vs Standard Care: Renal Replacement Therapy	2 of 228	5 of 237	465	NCT04362085	Trial comparisons
Therapeutic Anticoagulation vs Standard Care: Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days.	37 of 228	52 of 237	465	NCT04362085	Trial comparisons
Therapeutic Anticoagulation vs Standard Care: Red Blood Cell Transfusion	3 of 228	9 of 237	465	NCT04362085	Trial comparisons
Therapeutic Anticoagulation vs Standard Care: Transfusion of Platelets, Frozen Plasma, Prothrombin Complex Concentrate, Cryoprecipiate and/or Fibrinogen Concentrate	1 of 228	0 of 237	465	NCT04362085	Trial comparisons

1 to 10 of 25

See all 25 comparisons in its trials

Papers from its trials15

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
26591047	RESULT	1	PubMed
23935011	RESULT	1	PubMed
39116012	DERIVED	1	PubMed
37591523	DERIVED	1	PubMed
35244208	DERIVED	2	PubMed
34649864	DERIVED	1	PubMed
34268513	DERIVED	2	PubMed
33691765	DERIVED	1	PubMed
33502773	DERIVED	2	PubMed
33109923	DERIVED	1	PubMed

1 to 10 of 15

See all 15 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001531

GET https://conductscience.org/api/diseases/v1/MONDO_0001531/drugs?page=2

API reference For AI assistants